News about Global Pharma

US FDA Approves Regeneron's Otarmeni, First Gene Therapy for Genetic Hearing Loss

US Food and Drug Administration (FDA) approves Regeneron’s Otarmeni, the first AAV-based gene therapy, offering a potential treatment for severe-to-profound hearing loss.

Global Pharma | 27/04/2026 | By News Bureau |  128

AbbVie Provides US Regulatory Update on TrenibotE BLA

AbbVie gets US FDA Complete Response Letter (CRL) for TrenibotE BLA tied to manufacturing processes; no new clinical studies needed.

Global Pharma | 24/04/2026 | By News Bureau |  104

Integrated DNA Technologies Expands Manufacturing Capacity to Boost Cancer Research Solutions

Integrated DNA Technologies expands its Coralville facility, tripling production capacity to support faster, scalable solutions for cancer research and next-generation sequencing applications.

Global Pharma | 22/04/2026 | By News Bureau |  198

Syntegon Posts Record Year in 2025 and Aims for Further Growth

Syntegon reports a record 2025 with revenue up 10 percent to €1.75 billion and pharma sales surging 22 percent, alongside strong EBITDA and cash flow growth, reinforcing its position as a key lifecycle partner for pharma, biotech and food industries.

Global Pharma | 21/04/2026 | By News Bureau |  234

Interna Therapeutics and Daiichi Sankyo Partner to Advance MNM-Based Targeted Delivery Technology

Interna Therapeutics and Daiichi Sankyo collaborate to advance MNM-based targeted delivery technologies, aiming to enhance intracellular delivery, boost therapeutic activity, and improve performance across key drug development programs.

Global Pharma | 17/04/2026 | By News Bureau |  131

Mabwell Strengthens China Pipeline with NMPA Acceptance for Denosumab

Mabwell announces NMPA acceptance of its sBLA for MAIWEIJIAN (denosumab), China’s first approved 120mg denosumab biosimilar, used to treat giant cell tumor of bone in adults and adolescents.

Global Pharma | 17/04/2026 | By News Bureau |  102

Kazia Expands Oncology Platform with First-in-Class SETDB1 Inhibitor

Kazia Therapeutics expands its oncology platform with a first-in-class SETDB1 inhibitor, leveraging an AI-driven epigenetic drug discovery engine for faster and scalable candidate development.

Global Pharma | 15/04/2026 | By News Bureau |  150

Ifinatamab Deruxtecan Gets US Priority Review for Small Cell Lung Cancer

Ifinatamab deruxtecan receives US Priority Review for Small Cell Lung Cancer, supported by Phase 2 data, with potential as a first-in-class B7-H3 targeted Antibody Drug Conjugate.

Global Pharma | 13/04/2026 | By News Bureau |  168

Daiichi Sankyo Partners with Imagene AI for Biomarker Discovery

Through collaboration, Imagene AI and Daiichi Sankyo will apply multimodal AI to improve biomarker discovery with the goals of advancing precision oncology and enhancing clinical trial success rates.

Global Pharma | 11/04/2026 | By News Bureau |  170

Inventia Healthcare Launches Generic Dapagliflozin in US After FDA Approval

Inventia Healthcare has secured FDA approval for dapagliflozin tablets and begun Day-One commercialisation, expanding access to affordable diabetes and heart failure treatment in the US.

Global Pharma | 09/04/2026 | By News Bureau |  237